Table 2. Tumor assessment on octreotide and reasons for transitioning to lanreotide.

Tumor assessment on octreotide and reasons for transitioning to lanreotide, N=91	n	%
Radiologic assessment while being treated with long-acting octreotide monotherapy
Yes	75	82.4
No	11	12.1
Unknown	5	5.5
Disease status at last radiologic assessment while being treated with long-acting octreotide monotherapy	75	100.0
Nonprogressive disease	48	64.0
Progressive disease	24	32.0
Decrease in liver lesions	1	1.3
Unknown	2	2.7
Reasons for transitioning from long-acting octreotide to lanreotide monotherapy
Progressive disease (per clinician)	20	22.0
Formulary change	14	15.4
Patient preference	9	9.9
Injection-site complications	1	1.1
Insurance coverage	5	5.4
Other	17	18.7
Unknown	33	36.3
Composite disease status at end of long-acting octreotide treatment
Nonprogressive disease	52	57.1
Progressive diseasea	28	30.8
Unknown	11	15.5

^a, “Progressive disease” is comprised of patients who stopped treatment due to progressive disease and those with a “no” response to the question, “Did the patient have stable disease or responsive disease at the time of switching?” This does not account for patients who may have been determined to have progressive disease at the time of their last radiologic assessment while on octreotide.